New insider activity at Protagenic Therapeutics ( (PTIX) ) has taken place on August 24, 2026.

Executive Chair and Principal Officer Garo Armen has boosted his stake in Protagenic Therapeutics by purchasing 20,000 shares of the company’s stock, in a transaction valued at $13,000, signaling a notable vote of confidence from the firm’s leadership.

In the past day, Protagenic Therapeutics’ stock activity has been driven by two contrasting developments: supportive FDA feedback on its pre-IND package for PT00114 in generalized anxiety disorder, and a notification that its latest Form 10-Q will be filed late. The FDA’s endorsement of the planned Phase 1 design and CMC strategy improves clinical visibility, while the extended reporting delay heightens uncertainty around governance and financial execution, tempering sentiment despite no expected major earnings surprise.